Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress
Open accessThe DOI matches its Crossref record; 297 of the 301 references it cites were found in a registry or an index.
Abstract
Glucagon like-peptide 1 (GLP-1) within the brain is produced by a population of preproglucagon neurons located in the caudal nucleus of the solitary tract. These neurons project to the hypothalamus and another forebrain, hindbrain, and mesolimbic brain areas control the autonomic function, feeding, and the motivation to feed or regulate the stress response and the hypothalamic-pituitary-adrenal axis. GLP-1 receptor (GLP-1R) controls both food intake and feeding behavior (hunger-driven feeding, the hedonic value of food, and food motivation). The activation of GLP-1 receptors involves second messenger pathways and ionic events in the autonomic nervous system, which are very relevant to explain the essential central actions of GLP-1 as neuromodulator coordinating food intake in response to a physiological and stress-related stimulus to maintain homeostasis. Alterations in GLP-1 signaling associated with obesity or chronic stress induce the dysregulation of eating behavior. This review summarized the experimental shreds of evidence from studies using GLP-1R agonists to describe the neural and endocrine integration of stress responses and feeding behavior.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 The figure represents the effects of the central administration of GLP-1 and analogs on intake and some related behaviors schematically. The central administration of GLP-1 or analogs produces several physiological effects such as decreased food intake [158,206,230], water intake [171], and body weight [239]. Likewise, it also produces more related to food behavior effects, including increased CTA [169,170] and anorexia [220]. Besides some effects such the decreased of food-seeking [21,34,201,224] and food-motivated behavior [21,34].](https://figures.cochat.ai/paper-figures/a4a30c9f7c59468db5b49d377dbab50e/glucagon-like-peptide-1-glp-1-in-the-integration-of-neural-and-endocrine-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Peripherally, GLP-1 RAs influence gastrointestinal (GI) hormone secretion by inhibiting ghrelin, a key orexigenic hormone, and increasing peptide YY and cholecystokinin, which enhance satiety, facilitate digestion, and slow gastric emptying [5].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brown Adipose Tissue: Function and Physiological Significance
CANNON, B., & NEDERGAARD, J. (2004) · Physiological Reviews · doi:10.1152/physrev.00015.2003 · Cited by 6,433 · cited 1×
“Data in humans are conflictive since, although it has been demonstrated that GLP-1R agonist increases HR in healthy volunteers, obese subjects, and Type 2 diabetes mellitus (T2DM) patient, the role of the SNS it is not clear since some trials suggest an increase in SNS activity [157,158], but other studies found no ef…”
Effects of stress throughout the lifespan on the brain, behaviour and cognition
Lupien, S. J., McEwen, B. S., Gunnar, M. R., & Heim, C. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2639 · Cited by 6,256 · cited 1×
“Although the stress response is critical for survival in the short term, dysfunctional stress responses are linked to several somatic and psychiatric diseases, affective disorders, and neurodegenerative diseases, emphasizing the importance of precise neuronal control of effector pathways [124,125,127].”
BackgroundPhysiology and neurobiology of stress and adaptation: central role of the brain
McEwen, B. S. (2007) · Physiological Reviews · doi:10.1152/physrev.00041.2006 · Cited by 5,429 · cited 3×
“This response elicits rapid modifications in physiological states through neural innervation of end organs (increasing heart rate and blood glucose among others), and it is counter regulated and compensated by the parasympathetic (“rest and digest”) nervous system [38,125].”
BackgroundStress and the brain: from adaptation to disease
de Kloet, E. R., Joëls, M., & Holsboer, F. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1683 · Cited by 4,621
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Neural regulation of endocrine and autonomic stress responses
Ulrich-Lai, Y. M., & Herman, J. P. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2647 · Cited by 3,318
Stress and disorders of the stress system
Chrousos, G. P. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.106 · Cited by 3,215 · cited 1×
“Living organisms can survive because they maintain dynamic homeostasis, continuously challenged by internal or external adverse effects, termed stressors [123].”
BackgroundBrain corticosteroid receptor balance in health and disease
de Kloet, E. R., Vreugdenhil, E., Oitzl, M. S., & Joëls, M. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.3.0331 · Cited by 2,614
Brain corticosteroid receptor balance in health and disease
de Kloet, E. R. (1998) · Endocrine Reviews · doi:10.1210/er.19.3.269 · Cited by 2,614
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 1×
“GLP-1 is a member of the glucagon peptide superfamily, continuously secreted by the enteroendocrine L-cells at low basal levels in the fasting or interprandial state [14,15].”
Background
Cited by
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148
“This demonstrates that there may be differences in GLP-1 effects since GLP-1R expression may vary among species [32,85,86].”
BackgroundMethodSelf-citationKlen, J., & Dolžan, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073451 · Cited by 90
Bruns VI, N., Tressler, E. H., Vendruscolo, L. F., Leggio, L., & Farokhnia, M. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107312 · Cited by 89
Roles for the gut microbiota in regulating neuronal feeding circuits
Yu, K. B., & Hsiao, E. Y. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143772 · Cited by 88
Detka, J., & Głombik, K. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00274-8 · Cited by 79
Khan, M. T., Zohair, M., Khan, A., Kashif, A. W., Mumtaz, S., & Muskan, F. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2025.112599 · Cited by 77
Yang, F., Wang, X., Qi, J., Zhang, K., Jiang, Y., Feng, B., Lv, T., Yang, L., Yang, Q., Zhao, M., et al. (2022) · Nutrients · doi:10.3390/nu15010038 · Cited by 76
Insulin-resistance in paediatric age: Its magnitude and implications
Al‐Beltagi, M., Bediwy, A. S., & Saeed, N. K. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i4.282 · Cited by 70
Arillotta, D., Floresta, G., Papanti Pelletier, G. D., Guirguis, A., Corkery, J. M., Martinotti, G., & Schifano, F. (2024) · Brain Sciences · doi:10.3390/brainsci14060617 · Cited by 64
Marquez-Meneses, J. D., Olaya-Bonilla, S. A., Barrera-Carreño, S., Tibaduiza-Arévalo, L. C., Forero-Cárdenas, S., Carrillo-Vaca, L., Rojas-Rodríguez, L. C., Calderón‐Ospina, C., & Rodríguez, J. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115338 · Cited by 57
Patisaul, H. B. (2021) · Advances in pharmacology · doi:10.1016/bs.apha.2021.03.007 · Cited by 50
SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome
Gajjar, A., Raju, A. K. V., Gajjar, A. J., Menon, M., Shah, S. A. Y., Dani, S. S., & Weinberg, A. M. (2025) · Biomedicines · doi:10.3390/biomedicines13081924 · Cited by 49
Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological and Translational Insights
Alves, G. A. M., Teranishi, M., Ortega, A. C. T. D. C. G., James, F., & Arachchige, A. S. P. M. (2025) · Medical Sciences · doi:10.3390/medsci13030136 · Cited by 49
From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics
Roy, A., Dawson, V. L., & Dawson, T. M. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00712 · Cited by 47
Hormonal Regulation of Oxidative Phosphorylation in the Brain in Health and Disease
Głombik, K., Detka, J., & Budziszewska, B. (2021) · Cells · doi:10.3390/cells10112937 · Cited by 39
Effects of Glucagon-like peptide 1 (GLP-1) analogs in the hippocampus
Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., & Mallo, F. (2022) · Vitamins and hormones · doi:10.1016/bs.vh.2021.12.005 · Cited by 35
Self-citationVoros, C., Chatzinikolaou, F. G., Papapanagiotou, I., Polykalas, S., Mavrogianni, D., Koulakmanidis, A.-M., Athanasiou, D., Kanaka, V., Bananis, K., Athanasiou, A. I., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020759 · Cited by 34
Rroji, M., & Spasovski, G. B. (2024) · Biomedicines · doi:10.3390/biomedicines12030657 · Cited by 34
Teixeira, L. C. R., Luizon, M. R., & Gomes, K. B. (2025) · Receptors · doi:10.3390/receptors4010002 · Cited by 31
GLP-1 Receptor Agonists in Mood Disorders: A Psychiatric Perspective
Carmellini, P., Cuomo, A., Rescalli, M. B., & Fagiolini, A. M. (2025) · Life · doi:10.3390/life15091422 · Cited by 30
Aranäs, C., Caffrey, A., Edvardsson, C. E., Schmidt, H. D., & Jerlhag, E. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.07.001 · Cited by 30
Zhai, Y., Lu, K., Yuan, Y., Zhang, Z., Xue, L., Zhao, F., Xu, X., & Wang, H. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251329439 · Cited by 28
Magdy, Y., Kamar, S. A., Habib, M. Z., Rady, H. Y., Rabei, M. R., & Khedr, S. A. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06834-7 · Cited by 25
Lymperopoulos, A., Borges, J. I., & Stoicovy, R. A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060693 · Cited by 23
Incretins and the cardiovascular system: bridging digestion with metabolism
Avogaro, A., & Fadini, G. P. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00166-4 · Cited by 21
Tongta, S., Sungkaworn, T., & Pathomthongtaweechai, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262210974 · Cited by 21
Hoteit, B. H., Kotaich, J., Ftouni, H., Hazime, F., Safawi, A., Masri, R., & Marwani, M. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251383064 · Cited by 21
Rebalancing the Gut: Glucagon-Like Peptide-1 Agonists as a Strategy for Obesity and Metabolic Health
Singh, K., Aulakh, S. K., Nijjar, G. S., Singh, S., Sandhu, A. P. S., Luthra, S., Tanvir, F., Kaur, Y., Singla, A., & Kaur, M. S. (2024) · Cureus · doi:10.7759/cureus.64738 · Cited by 18
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 17
Potential new therapeutic target for Alzheimer's disease: Glucagon‐like peptide‐1
Liu, X., Zhang, N., Zhang, S., & Xu, P. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15502 · Cited by 17
Abu-Nejim, H., & Becker, R. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01350-7 · Cited by 16
GLP-1 receptor agonists as promising disease-modifying agents in WFS1 spectrum disorder
Panfili, E., Frontino, G., & Pallotta, M. T. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1171091 · Cited by 16
Mostafa, M. E. A., & Alrasheed, T. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1548346 · Cited by 16
GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective
d’Ávila, M., Hall, S., & Horváth, T. L. (2024) · Endocrinology · doi:10.1210/endocr/bqae128 · Cited by 14
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
Alluri, A. A., Kurien, M. M., Pokar, N. P., Madarapu, A., Sadam, S., Puvvala, N., & Seetharaman, R. (2025) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2024-0193 · Cited by 13
Control of human pancreatic beta cell kinome by glucagon‐like peptide‐1 receptor biased agonism
Xiao, J., Eid, L. E., Buenaventura, T., Boutry, R., Bonnefond, A., Jones, B. J., Rutter, G. A., Froguel, P., & Tomás, A. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15083 · Cited by 13
Wang, X.-Y., Liu, Y., Cao, L.-X., Li, Y.-Z., Wan, P., & Qiu, D. (2023) · Scientific Reports · doi:10.1038/s41598-023-34070-6 · Cited by 12
Does Incretin Agonism Have Sustainable Efficacy?
Janket, S., Chatanaka, M. K., Sohaei, D., Tamimi, F., Meurman, J. H., & Diamandis, E. P. (2024) · Cells · doi:10.3390/cells13221842 · Cited by 11
Gut microbiota and stress ulcers: unraveling the neurotransmitter connection
Abdel-Sater, K. A., & Hassan, H. A. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1594179 · Cited by 11
Jin, F., Wang, Y., Li, M., Li, R.-J., & Guo, J. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i8.1764 · Cited by 11
Ion transporter cascade, reactive astrogliosis and cerebrovascular diseases
Rahman, M. S., Islam, R., & Bhuiyan, M. I. H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1374408 · Cited by 10
The Intricate Relationship between Circadian Rhythms and Gastrointestinal Peptides in Obesity
Ribeiro, F. M., Arnaldo, L., P. Milhomem, L., S. Aguiar, S., & Franco, O. L. (2025) · Peptides · doi:10.1016/j.peptides.2025.171356 · Cited by 9
Koufakis, T., Kokkinos, A. D., & le Roux, C. W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70723 · Cited by 9
Reytor-González, C., Cevallos-Fernández, E., Jácome, B., & Simancas-Racines, D. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1655889 · Cited by 9
Casteràs, A., Fidilio, E., Comas, M., Zabalegui, A., Flores, V., Giralt, M., Troyano, N. D., Ferrer, R., Vilallonga, R., Ciudin, A., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13175146 · Cited by 8
Baumer-Harrison, C., Graham, M., Jonghe, B. C. D., & Hayes, M. R. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.06.015 · Cited by 8
Exploring the Mechanisms of Gastroesophageal Reflux Disease Based on the Brain-Gut Axis Theory
Du, S., Zhang, L., Chen, Y., Zhang, Q., Chen, B., & Chen, S. (2025) · International Journal of General Medicine · doi:10.2147/ijgm.s558504 · Cited by 8
Gelfand, S. T., Tveit, M., & Simon, J. A. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100233 · Cited by 8
Hsu, C.-C., Cheng, J., Hsu, P. H., Li, Y., & Cheng, K. (2022) · Pharmaceuticals · doi:10.3390/ph15070904 · Cited by 8
GLP-1 Receptor Agonists: Beyond Diabetes—What the Neurosurgeon Needs to Know
Abdulrazeq, H., Taman, M., Ali, R., Doberstein, C., Sullivan, P. Z., Sampath, P., Telfeian, A. E., Gokaslan, Z. L., Fridley, J., & Asaad, W. F. (2024) · Neurosurgery Open · doi:10.1227/neuprac.0000000000000098 · Cited by 7
Senesi, P., Ferrulli, A., Luzi, L., & Terruzzi, I. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.975509 · Cited by 7
Nurkolis, F., Delarue, J., Lau, V., Syahputra, R. A., Tsopmo, A., Hardinsyah, H., Prieto, M. A., Taslim, N. A., Tallei, T. E., Tjandrawinata, R. R., et al. (2025) · Phytotherapy Research · doi:10.1002/ptr.70116 · Cited by 7
GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease
Gandhi, A., Phyu, E. M., Koom‐Dadzie, K., Dickson, K. B., & Halm, J. K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062853 · Cited by 6
GLP-1 Receptor Agonist Medications: Interactions With Addiction Neurocircuitry
Volkow, N. D., Brucar, L. R., & Fink‐Jensen, A. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.01.011 · Cited by 6
Wang, L., Hu, T., Zhang, R., Shi, Y., Wang, Y., Xuan, Q., & Zhou, X. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151583 · Cited by 6
When Gut Hormones Influence Brain Function in Depression
Siba, I. P., Martynhak, B. J., & Pereira, M. (2023) · Applied Biosciences · doi:10.3390/applbiosci2010005 · Cited by 5
Tang, H., Lu, Y., Zhang, B., Zhang, D., Asch, D. A., & Chen, Y. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103857 · Cited by 5
Glucagon-like peptide-1 and impaired counterregulatory responses to hypoglycemia in type 1 diabetes
Rocha, G. R., & de Melo, F. F. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.99928 · Cited by 4
Song, E., Fang, Y., Li, X., Fu, W., He, H., Gao, Z., Tian, X., & Gao, B. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1809416 · Cited by 3
Zheng, L., Li, G., Liu, Y., & Hou, Z. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02958-4 · Cited by 3
Stapleton, H. M., Borges, D. D. S., Trindade, E. B. S. D. M., & Yuan, Q. (2026) · Biology of Sex Differences · doi:10.1186/s13293-026-00834-8 · Cited by 3
GLP-1 enhances hyperpolarization-activated currents of mouse cerebellar Purkinje cell in vitro
Liu, Y., Cao, L.-X., Wang, W., Piao, Y.-R., Wang, J.-Y., Chu, C., Bing, Y.-H., & Qiu, D. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1126447 · Cited by 3
Waheed, I., Sikandri, T., Zaheen, S., Khakwani, M. M. A. K., An, Z., Liu, T., Zhu, C., & Wei, J. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00819 · Cited by 3
GLP-1 receptor agonists and smoking cessation: therapeutic promise beyond glycemia
Bhaduri, G., Mukherjee, S., Parikh, R. M., Karak, S., & Pal, J. (2026) · Endocrine · doi:10.1007/s12020-026-04559-x · Cited by 2
Glucagon-like peptide-1 receptor agonists and hair loss: Current evidence and potential mechanisms
Spindler, A. J., Maas, D., Rachko, G., Zappi, I., Kapur, S. K., Sidhu, K. S., Maas, K., Garza-García, L. M., Patrocínio, J., Petukhova, L., et al. (2026) · JAAD reviews. · doi:10.1016/j.jdrv.2026.07.002 · Cited by 2
Abolfazli, S., Atkin, S. L., Jamialahmadi, T., & Sahebkar, A. (2025) · Glycoconjugate Journal · doi:10.1007/s10719-025-10197-8 · Cited by 2
Effects of chronic ethanol consumption on brain GLP-1R gene expression in mice and humans
Torregrosa, A. B., García‐Gutiérrez, M. S., Ortuño‐Miquel, S., & Manzanares, J. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03838-5 · Cited by 2
Antiepileptic effects of exenatide in penicillin induced acute epilepsy model in rats
Yildiz, A., Kocacan, S. E., & Him, A. (2023) · Indian Journal of Experimental Biology · doi:10.56042/ijeb.v61i06.1931 · Cited by 2
Maradia, J., Joshi, S. S., Koli, P. G., Radhakrishnan, M., & Athavale, C. (2026) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj-d-25-00078 · Cited by 1
Glucagon-Like Peptide-1 Receptor Agonists in Pregnancy: Promises, Pitfalls, and the Path Forward
Eke, A. C. (2026) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000006021 · Cited by 1
Wicik, Z., Nowak-Szwed, A., Eyileten, C., Sourij, H., von Lewinski, D., Kistkins, S., Borkowska, J., & Postula, M. A. (2025) · npj Systems Biology and Applications · doi:10.1038/s41540-025-00619-6 · Cited by 1
Verma, J., Singh, R. K., Paul, S., Gupta, S., Gupta, A. K., Sharma, A. K., Kumar, M., Mehan, S., Samant, R., & Tongra, M. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01866-0 · Cited by 1
Reitz, J., Rosoff, D. B., Pacher, P., & Lohoff, F. W. (2026) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2026.100793 · Cited by 1
Caplin, A., & Fraser, R. I. (2026) · The Canadian Journal of Addiction · doi:10.1097/cxa.0000000000000268 · Cited by 1
Chhabra, V., Bartwal, S. S., Hameed, S., & Kumar, N. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11497-3 · Cited by 1
Melamed, B., Parsi‐Zahabi, M., Omrani, M. A., Baskaran, B. S., Eddin, L. E., Kermanshahi, N., Chalabianloo, N., & Muanda, F. T. (2026) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70517 · Cited by 1
Extending Healthspan via GLP-1 Receptor Agonist: Insights and Perspectives
Chakrabarti, S. K., & Chattopadhyay, D. (2026) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2025.00036 · Cited by 1
A current grasp of GLP-1 receptor agonists for addiction: emerging therapeutic potential
Moosa-Battey, R. (2025) · SA pharmaceutical journal. · doi:10.36303/sapj.2615 · Cited by 1
Stress, neurotransmitters, and the microbiota–gut–brain axis: mechanisms of mucosal injury
Abdel-Sater, K. A. (2025) · Research Results in Pharmacology · doi:10.18413/rrpharmacology.11.587 · Cited by 1
Acute Psychological Stress and Food Intake in Humans: A Scoping Review
Clause-Walford, D. (2021) · doi:10.82465/4506 · Cited by 1
Bahathig, A. M., Alghamdi, A. H., Aljaffer, M. A., Alblowi, M. A., Alotaibi, M. S., AlNouwaiser, D. N., Alshehri, A. M., Alhejji, A. M., Alruwaili, W. S., Abuseif, G. A., et al. (2026) · Healthcare · doi:10.3390/healthcare14081049 · Cited by 1
Dao, M. Q., Kim, A. Y., Wang, S., Won, P., Laspro, M., Gillenwater, T. J., Yenikomshian, H. A., & Johnson, M. B. (2025) · Burns · doi:10.1016/j.burns.2025.107848
New Approaches to Regulating Gonadal and Thyroid System Activity
Shpakov, A. O., & Derkach, K. V. (2026) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093026040022
EFEITOS TERAPÊUTICOS DOS AGONISTAS DO RECEPTOR DO GLP-1: UM ESTUDO DE REVISÃO
Gonçalves, F. M., Araújo, F. D. S., Barbosa, G. F., Presoto, C. L. Z., & Gardizani, T. P. (2025) · Revista Omnia Saúde · doi:10.69719/ros.v8.862
Music Medicine for Neurological Disorders
Chauhan, N. B., Kale, M., Gujar-Kale, P., Desai, M., Jain, D. K., & Iyer, A. (2024) · Integrated science · doi:10.1007/978-3-031-73061-0_26
Glucagon-like-peptide-1 and Mental Health
O’Connor, M. A., Peters, A., & Reddin, C. J. (2025) · Nursing Clinics of North America · doi:10.1016/j.cnur.2025.09.005
Lakshmi, S. M., Singh, V., Vanangamudi, M., Taj, T., Shahin, H., Nath, R., Dutta, G., Avvari, S. K., Sridhar, S. B., Panigrahy, U. P., et al. (2026) · European Journal of Neuroscience · doi:10.1111/ejn.70718
RNA binding protein HuD regulates the biosynthesis of glucagon-like peptide 1 in intestinal L-cells
Han, S., Jung, M., Ryu, S., Cha, S., Tak, H., Jeong, S. M., & Lee, E. K. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.102415
Metformin or GLP 1 Receptor Agonists? Current Views on the Management of Polycystic Ovary Syndrome
Szwankowska, A. A., Boruszczak, B., Pilarska, K. J., Kołodziej-Sieradz, M., Ćwiek, H. J., Gryz, P. K., Baczyńska, A., Terlecka, A. M., Komorowski, K., & Rożenek, A. W. (2026) · Archiv Euromedica · doi:10.35630/2026/16/iss.2.9
Palm, U., Backmund, M., & Himmerich, H. (2026) · Frontiers in Drug Safety and Regulation · doi:10.3389/fdsfr.2026.1880796
Duh, M., & Stožer, A. (2025) · Medicinski razgledi · doi:10.61300/mr640404
Tonin, G., & Klen, J. (2025) · DiRROS repository (University of Maribor)
Bregar, M. (2026) · Repository of the University of Ljubljana (University of Ljubljana)
Kato Jumba, K. (2026) · NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY · doi:10.59298/nijpp/2026/716269
Veisi, M., Bae, J., & Jung, Y. (2026) · Drug Targets and Therapeutics · doi:10.58502/dtt.26.0010
Gut–Brain–GLP-1 Axis Beyond Glycemic Control: Emerging Neuroprotective and Anti-Obesity Mechanisms
Kosey, S. (2026) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2026.18.555998
Rye, C. S., Baker, G., & Milton, A. L. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04425-4
Cordeanu, E. (2025) · theses.fr (ABES) · doi:10.70675/8b5ff9afzf076z4b51zae9azb68b119a0c07
Metadata
- Authors
- Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., Lamas, J. A., & Mallo, F.
- Affiliations
- Universidade de Vigo (ES)
- Corresponding author
- Diz-Chaves, Yolanda
- Mallo, Federico
- ORCID
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2020-10-28
- Volume
- 12
- Issue
- 11
- Pages
- 3304
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC7692797
- OpenAlex
- W3096746160
- Cited by
- 84
- References
- 301
- Citations by year
- 2026: 19 · 2025: 33 · 2024: 13 · 2023: 7 · 2022: 7 · 2021: 5
- FWCI
- 0.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Investigo Institutional repository of UVigo (Universidade de Vigo) (submittedVersion, cc-by)
- Funders
- European Commission
- Xunta de Galicia (CN 2012/273, GPC2015/022, ED-431G/02, ED431G)
- Centro Singular de Investigación de Galicia (ED431G)
- European Regional Development Fund (2016-2019)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucagon-like peptide-1, GLP-1 receptor, nucleus tractus solitarius, hypothalamus, hypothalamic-pituitary-adrenal axis, stress response, feeding behavior, food intake regulation, food motivation, obesity, chronic stress, GLP-1 receptor agonists, autonomic nervous system, homeostasis
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Brain, Feeding Behavior, Humans, Hypothalamo-Hypophyseal System, Neurons, Pituitary-Adrenal System, Stress, Physiological, Signal Transduction, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.